Key Figures Q2 2020
|
SEK m, unless otherwise stated |
2020 Apr-Jun |
2019 Apr-Jun |
2020 Jan-Jun |
2019 Jan-Jun |
2019 Jan-Dec |
2019-2020 Apr-Jun Δ |
|
Net revenues |
179.1 |
201.2 |
354.2 |
375.5 |
844.8 |
-11% |
|
Cost of goods sold |
-19.9 |
-31.3 |
-39.9 |
-56.6 |
-105.6 |
-36% |
|
Operating expenses |
-172.5 |
-117.1 |
-293.6 |
-265.1 |
-508.0 |
47% |
|
EBIT |
-13.3 |
52.8 |
20.7 |
53.8 |
231.2 |
-125% |
|
EBITmargin, % |
-7.4 |
26.2 |
5.8 |
14.3 |
27.4 |
-33.7 ppt |
|
EBITDA |
-9.0 |
60.4 |
30.1 |
72.3 |
272.1 |
-115% |
|
Earnings per share, before dilution, SEK |
-0.94 |
1.54 |
1.44 |
1.93 |
6.33 |
-161% |
|
Earnings per share, after dilution, SEK |
-0.94 |
1.51 |
1.44 |
1.90 |
6.20 |
-162% |
|
Cash flow from operating activities |
-7.2 |
46.1 |
40.9 |
97.1 |
287.0 |
-116% |
|
Cash and cash equivalents |
677.2 |
697.0 |
677.2 |
679.0 |
816.8 |
-3% |
Net revenues and EBIT per segment Q2 2020
|
SEK m |
Net Revenues |
EBIT |
||||||||
|
|
2020 Apr-Jun |
2019 Apr-Jun |
2020 Jan-Jun |
2019 Jan-Jun |
2019 Jan-Dec |
2020 Apr-Jun |
2019 Apr-Jun |
2020 Jan-Jun |
2019 Jan-Jun |
2019 Jan-Dec |
|
ZUBSOLV® US |
172.5 |
184.4 |
336.4 |
346.1 |
719.2 |
- |
- |
- |
- |
- |
|
US Pharma – total |
172.5 |
184.4 |
336.4 |
346.1 |
719.2 |
88.8 |
83.8 |
164.5 |
152.0 |
347.1 |
|
Digitala Therapeutics |
- |
- |
- |
- |
- |
-35.5 |
- |
-47.6 |
- |
-0.9 |
|
Digitala Therapeutics – total |
- |
- |
- |
- |
- |
-35.5 |
- |
-47.6 |
- |
-0.9 |
|
Abstral® royalties |
3.5 |
13.1 |
12.2 |
24.0 |
112.6 |
- |
- |
- |
- |
- |
|
Edluar® royalties |
3.1 |
2.4 |
5.5 |
4.2 |
11.6 |
- |
- |
- |
- |
- |
|
ZUBSOLV® - ex US |
- |
- |
0.1 |
- |
0.1 |
- |
- |
- |
- |
- |
|
OX-MPI |
- |
1.3 |
- |
1.3 |
1.4 |
- |
- |
- |
- |
- |
|
HQ & Pipeline – total |
6.6 |
16.8 |
17.8 |
29.4 |
125.6 |
-66.6 |
-31.0 |
-96.2 |
-98.1 |
-115,0 |
|
Total |
179.1 |
201.2 |
354.2 |
375.5 |
844.8 |
-13.3 |
52.8 |
20.7 |
53.8 |
231,2 |
Cash flow Q2 2020
|
SEK m |
2020 Apr-Jun |
2019 Apr-Jun |
2020 Jan-Jun |
2019 Jan-Jun |
2019 Jan-Dec |
|
Cash flow from operating activities |
-7.2 |
46.1 |
40.9 |
97.1 |
287.0 |
|
Investment activities |
-106.0 |
-0.8 |
-109.9 |
-0.8 |
-22.4 |
|
Financing activities |
-33.9 |
-3.8 |
-102.7 |
-14.5 |
-53.7 |
|
Cash flow (excl exchange rate differences) |
-147.1 |
41.6 |
-171.7 |
81.7 |
210.8 |
|
Liquid funds |
677.2 |
697.0 |
677.2 |
697.0 |
816.8 |
